ITabMed Ltd. is a clinical-stage biotech company developing immunotherapy antibodies (ITAbTM) to treat cancer and autoimmune disease. Our tri-specific T cell engager (TriTE) platform generates first-in-class and best-in-class tri-specific antibodies with the capabilities to overcome the hurdles in the current cancer immunotherapies, such as antigen escape, T cell exhaustion and targeting very low levels of tumor-specific antigens (TSA). Our TriTE-8S selectively activates CD8 T cells aiming to treat solid tumors.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Shanghai
Company HQ Country:
China
Year Founded:
2020
Main Therapeutic Focus:
Oncology
Lead Product in Development:
A-319 to treat r/r B-ALL, and r/r NHL
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5
Speaker
